It demonstrated that immunotherapy, along with human epidermal growth factor receptor 2 (HER2)‐targeted therapy and chemotherapy, was highly beneficial in treating HER2‐positive gastric cancer (GC). Here, ERBB2 is linked to gastric cancer.